As of June 18, 2025, Zynerba Pharmaceuticals Inc (ZYNE) reports a ROE (Return on Equity) of -75.79%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Zynerba Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Zynerba Pharmaceuticals Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | -75.79% |
| 2021-12-31 | -52.61% |
| 2020-12-31 | -85.37% |
| 2019-12-31 | -43.57% |
| 2018-12-31 | -69.29% |
This slight downward trend highlights how Zynerba Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Zynerba Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Zynerba Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Zynerba Pharmaceuticals Inc (ZYNE) | -75.79% |
| Hepion Pharmaceuticals Inc (HEPA) | 708.00% |
| Iterum Therapeutics PLC (ITRM) | 612.59% |
| Eloxx Pharmaceuticals Inc (ELOX) | 338.32% |
| Baudax Bio Inc (BXRX) | 242.57% |
| Weed Inc (BUDZ) | 231.08% |
Compared to its competitors, Zynerba Pharmaceuticals Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.